Dysregulated Glial Differentiation in Schizophrenia May Be Relieved by Suppression of SMAD4- and REST-Dependent Signaling by Liu, Zhengshan et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Dysregulated Glial Differentiation in Schizophrenia May Be Relieved by Suppression of
SMAD4- and REST-Dependent Signaling
Liu, Zhengshan; Osipovitch, Mikhail; Benraiss, Abdellatif; Huynh, Nguyen P.T.; Foti, Rossana;
Bates, Janna; Chandler-Militello, Devin; Findling, Robert L.; Tesar, Paul J.; Nedergaard,
Maiken; Windrem, Martha S.; Goldman, Steven A.
Published in:
Cell Reports
DOI:
10.1016/j.celrep.2019.05.088
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Liu, Z., Osipovitch, M., Benraiss, A., Huynh, N. P. T., Foti, R., Bates, J., ... Goldman, S. A. (2019). Dysregulated
Glial Differentiation in Schizophrenia May Be Relieved by Suppression of SMAD4- and REST-Dependent
Signaling. Cell Reports, 27(13), 3832-3843, e1-e6. https://doi.org/10.1016/j.celrep.2019.05.088
Download date: 03. Feb. 2020
ArticleDysregulated Glial Differentiation in Schizophrenia
May Be Relieved by Suppression of SMAD4- and
REST-Dependent SignalingGraphical AbstractHighlightsd Dysregulated BMP signaling restricts the differentiation of
SCZ glial progenitor cells
d REST is regulated by BMP/SMAD4 signaling and is
overexpressed by SCZ GPCs
d SMAD4 knockdown rescues normal astrocytic differentiation
by SCZ GPCs
d REST knockdown rescues K+ transporter gene expression
and K+ uptake by SCZ gliaLiu et al., 2019, Cell Reports 27, 3832–3843
June 25, 2019 ª 2019 The Authors.
https://doi.org/10.1016/j.celrep.2019.05.088Authors
Zhengshan Liu, Mikhail Osipovitch,
Abdellatif Benraiss, ...,
Maiken Nedergaard, Martha S. Windrem,
Steven A. Goldman
Correspondence
steven_goldman@urmc.rochester.edu,
goldman@sund.ku.dk
In Brief
Astrocytic differentiation is impaired in
childhood-onset schizophrenia (SCZ). Liu
et al. report that SMAD4-dependent BMP
signaling and REST are upregulated in
hiPSC-derived SCZ glia and that SMAD4
and REST knockdown rescue both
astroglial differentiation and K+ transport.
SCZ astrocytic maturation may thus be
rescued by targeting SMAD4- and REST-
dependent transcription.
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Astrocytic differentiation is developmentally impaired
in patients with childhood-onset schizophrenia (SCZ).
To determinewhy, we used genetic gain- and loss-of-
function studies to establish the contributions of
differentially expressed transcriptional regulators to
the defective differentiation of glial progenitor cells
(GPCs) produced from SCZ patient-derived induced
pluripotent cells (iPSCs). Negative regulators of the
bonemorphogenetic protein (BMP) pathwaywere up-
regulated in SCZ GPCs, including BAMBI, FST, and
GREM1, whose overexpression retained SCZ GPCs
at the progenitor stage. SMAD4 knockdown (KD) sup-
pressed the production of these BMP inhibitors by
SCZ GPCs and rescued normal astrocytic differentia-
tion. In addition, the BMP-regulated transcriptional
repressor REST was upregulated in SCZ GPCs, and
its KD similarly restored normal glial differentiation.
REST KD also rescued potassium-transport-associ-
ated gene expression and K+ uptake, which were
otherwise deficient in SCZ glia. These data suggest
that the glial differentiation defect in childhood-onset
SCZ, and its attendant disruption in K+ homeostasis,
may be rescued by targeting BMP/SMAD4- and
REST-dependent transcription.INTRODUCTION
Schizophrenia (SCZ) affects roughly 1% of the population world-
wide and has been the focus of increasingly fruitful efforts to un-
derstand its genetic foundations; nonetheless, its cellular basis
remains poorly understood (Allen et al., 2008; Sawa and Snyder,
2002). Yet recent reports, including both genome-wide associa-
tion and differential expression studies, have linked a number of
candidate loci as well as specific differentially expressed genes3832 Cell Reports 27, 3832–3843, June 25, 2019 ª 2019 The Authors
This is an open access article under the CC BY-NC-ND license (http://to schizophrenic pathogenesis (Fromer et al., 2016; Marshall
et al., 2017; Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014). Over the past decade in partic-
ular, it has become clear that a number of these SCZ-associated
genes are involved in the development and physiology of glial
cells (Takahashi and Sakurai, 2013; Takahashi et al., 2011a,
2011b; Yin et al., 2012). Accordingly, both astrocytic and oligo-
dendrocytic dysfunction has been implicated in the etiology of
SCZ (Aberg et al., 2006; Fields, 2008; Goudriaan et al., 2014;
Tkachev et al., 2003; Voineskos et al., 2013; Wang et al.,
2015). Astrocytes in particular have essential roles in both the
structural development of neural networks as well as the coordi-
nation of neural circuit activity, the latter through their release of
glial transmitters, maintenance of synaptic density, and regula-
tion of synaptic potassium and neurotransmitter levels (Christo-
pherson et al., 2005; Chung et al., 2013; Rangroo Thrane et al.,
2013). As such, defective astrocytic maturation may be an
important contributor to the neural circuit disruption character-
istic of SCZ (Singh et al., 2016; Verkhratsky and Parpura, 2016;
Xia et al., 2016).
To investigate the role of glial pathology in SCZ as well as other
neuropsychiatric disorders, we first established a protocol for
generating human glial progenitor cells (hGPCs) from patient-
derived induced pluripotent cells (iPSCs) (Wang et al., 2013).
This protocol permits us to generate hGPCs and their derived
astrocytes and oligodendrocytes from patients with SCZ, in a
manner that preserves their genetic integrity and functional reper-
toires. As such, this method has provided us a means by which to
assess the differentiation, gene expression, and functional
competence of astrocytes derived from patients with SCZ, both
in vitro and in vivo, the latter after engraftment into immunodefi-
cient mice (Windrem et al., 2017). We found that such glial
chimeric mice, when neonatally colonized with iPSC-derived
hGPCs produced from patients with childhood-onset SCZ, ex-
hibited profound abnormalities in both astrocytic differentiation
and structure; these were associated with significant behavioral
abnormalities in the engrafted mice relative to controls implanted
with normal human hGPCs. Importantly, RNA sequence analysis
revealed that the maturational defects in these SCZ hGPCs.
creativecommons.org/licenses/by-nc-nd/4.0/).
were associated with the downregulation of a core set of
differentiation-associated genes, whose transcriptional targets
included a host of transporters, channels, and synaptic modula-
tors that were themselves deficient in SCZ glia (Windrem et al.,
2017).
In the present study, we sought to capitalize upon these find-
ings by identifying targetable signaling nodes at which SCZ-
associated glial pathology might be moderated. To that end,
we generated iPSC hGPCs from patients with childhood-onset
SCZ, or from normal control (CTR) subjects, and then
compared both the patterns of gene expression and extent of
astrocytic functional differentiation by these cells. We found
that excessive bone morphogenetic protein (BMP)-dependent
signaling plays a critical role in the disrupted astroglial differen-
tiation of SCZ hGPCs, that BMP’s actions in this context are
signaled through SMAD4 and mediated in part by a compensa-
tory upregulation of endogenous BMP antagonists, and that as-
pects of normal phenotype may then be restored to SCZ glia by
SMAD4 knockdown (KD). Since the preservation of K+ homeo-
stasis is a critical element of astrocytic function, and our RNA
sequencing (RNA-seq) data indicated the downregulation of a
number of potassium channels, pumps, and transporters (here-
after referred to simply as potassium transporters) by SCZ glia,
we then assessed the uptake of K+ by SCZ astrocytes. We
found that the SCZ cells indeed manifested significantly
impaired K+ uptake relative to CTR astrocytes and, moreover,
that aberrant expression of the REST repressor was respon-
sible for their diminished transcription of the potassium trans-
porter genes. Together, these studies highlight the dysregula-
tion of glial BMP/SMAD4- and REST-dependent transcription
as important contributors to the pathogenesis of SCZ and iden-
tify these as intriguing new targets for rescuing both glial
phenotype and function in this disorder.
RESULTS
Astrocytic Differentiation Was Impaired in SCZ GPCs
iPSCs were produced from skin samples obtained from patients
with childhood-onset SCZ, as well as healthy young adult CTRs
free of known mental illness, as previously described (Windrem
et al., 2017). Patient identifiers were not available to investigators
besides the treating psychiatrist, although age, gender, race,
diagnosis, and medication history accompanied cell line identi-
fiers. Briefly, fibroblasts were isolated from each sample; from
these, 8 human-induced pluripotent stem cell (hiPSC) lines
were derived from patient samples and normal CTRs (5 juve-
nile-onset SCZ patients and 3 healthy gender-matched and
age-analogous CTRs; Table S1). iPSCs were generated using
excisable floxed polycistronic hSTEMCCA lentivirus (Somers
et al., 2010; Zou et al., 2012) encoding Oct4, Sox2, Klf4, and
c-Myc (Takahashi et al., 2007; Welstead et al., 2008). A fourth
hiPSC CTR line, C27 (Chambers et al., 2009), was also used,
to ensure that all genomic and phenotypic data were consistent
with prior work in our lab (Wang et al., 2013). All lines were vali-
dated as pluripotent using RNA-seq and immunolabeling to
assess pluripotent gene expression. The identity of each iPSC
line was confirmed to match the parental donor fibroblasts using
short tandem repeat (STR)-based DNA fingerprinting, and eachline was karyotyped and arrayed for comparative genomic hy-
bridization to confirm genomic integrity. In addition, these iPSC
lines were arrayed for genome-wide methylation to compare
their methylation state.
We first compared the glial differentiation efficiency of cells
derived from SCZ patients and control subjects (n = 4 lines
from 4 different patients, each with R 3 repeats/patient, each
versus paired CTR), by instructing these iPSC cells to GPC fate
as previously described (Wang et al., 2013) and assessing their
expression of stage-specific markers of maturation as a function
of time.We found that all tested iPSCs exhibited typical colonies,
and expressed markers of pluripotency by flow cytometry,
including SSEA4 (Figure S1A). At the neural progenitor cell
(NPC) stage, both immunocytochemistry (ICC) and flow cytome-
try revealed that the expression levels of the stage-selective
markers paired box protein pax-6 (PAX6), sex determining region
Y-box 1 (SOX1), and the cell surface marker prominin-1/CD133
were no different between CTR- and SCZ-derived lines (Figures
1A–1D; Figure S1B). At the GPC stage, their expression of the
GPC-selective platelet-derived growth factor receptor alpha
(PDGFRa/CD140a) (Sim et al., 2011) was then assessed, which
revealed that the efficiencies of GPC generation did not differ
significantly between SCZ- and CTR-derived NPCs (Figures
1E–1G; Figure S1C). At the astrocytic progenitor stage, the
flow cytometry confirmed that the expression levels of cell sur-
face marker CD44 were no different between CTR- and SCZ-
derived lines (Figure S1D). Thus, no differences in the differenti-
ation of SCZ and CTR iPSCs were noted through the GPC and
astrocytic progenitor stages.
At that point, the SCZ- and CTR-derived GPCs were further
differentiated into astrocytes by incubating in M41 medium sup-
plemented with 20 ng/ml BMP4 for 4 weeks. Immunolabeling re-
vealed that the proportion of GFAP+ astrocytes was significantly
higher in CTR lines (4 CTR lines, nR 3 per line, mean of 4 CTR
lines = 70.1% ± 2.4%) than in SCZ lines (4 SCZ lines, n R 3
per line, mean of 4 SCZ lines = 39.9% ± 2.0%; p < 0.001, two-
tailed t test) (Figures 1H–1J). In addition to GFAP, the percentage
of S100b+ astrocytes was also significantly higher in CTR lines
relative to SCZ lines (Figure S1F). In contrast, the proportion of
PDGFaR+ GPCs was significantly higher in BMP4-treated SCZ
glia (4 SCZ lines, n R 3 per line) relative to BMP4-treated CTR
glia (4 CTR lines, nR 3 per line) (Figure S1E). This defect of as-
trocytic differentiation was consistently observed in all SCZ
GPCs relative to CTR cells and comprised an in vitro correlate
to previously described astroglial differentiation defects in vivo
(Windrem et al., 2017).
SCZ GPCs Upregulated Expression of BAMBI, an
Inhibitor of BMP Signaling
To identify the molecular concomitants to the defective astro-
cytic differentiation of SCZ GPCs, we had earlier performed
RNA-seq on fluorescence-activated cell sorting (FACS)-sorted
CD140a+ GPCs from 3 different CTR- and 4 SCZ-derived lines
at time points ranging from 154 to 242 days in vitro (Windrem
et al., 2017). mRNA was isolated from these cells with polyA-
selection for RNA-seq on an Illumina HiSeq 2500 platform for
approximately 45 million 1x100 bp reads per sample. The orig-
inal counts were analyzed to determine disease-dysregulatedCell Reports 27, 3832–3843, June 25, 2019 3833
Figure 1. Astrocytic Differentiation Was
Impaired in SCZ GPCs
(A–D) At the neural progenitor cell (NPC) stage, both
CTR (A) andSCZ (B) hNPCs (representative examples
of lines derived from 4 distinct patients, n R 3/each
line) highly expressed both SOX1 (C) and PAX6 (D).
(E–G) Similarly, the efficiency of PDGFRa/CD140a-
defined hGPC generation (G) did not differ between
CTR (E) and SCZ (F) lines (4 different patient-specific
lines each, nR 3/each line).
(H–J) In contrast, the proportion of GFAP+ astrocytes
(J) was significantly higher in CTR cultures (H; 4 CTR
lines, n R 3/each line [70.1% ± 2.4%]) than in iden-
tically raised SCZ cultures (I; 4 SCZ lines, nR 3/each
line [39.9% ± 2.0%]).
Scale: 50 mm; ***p < 0.001 by two-tailed t test;NS, not
significant; mean ± SEM.genes at 5% false discovery rate (FDR) and log2 fold change > 1.
By that means, we had identified 118 mRNAs that were consis-
tently and significantly differentially expressed by CD140a-
sorted SCZ hGPCs relative to their CTR iPSC hGPCs (Windrem
et al., 2017). Among these, a number of genes involved in glial
lineage progression were downregulated in SCZ hGPCs relative
to their normal CTRs, suggesting that astroglial differentiation
was impaired in SCZ in a cell-autonomous fashion, due to
intrinsic defects in SCZ-derived GPCs.
Capitalizing upon these earlier data, in this study we first used
Ingenuity Pathway Analysis (IPA) to identify pathways that were
significantly differentially regulated in SCZ hGPCs. We found
that among these, BMP-signaling-related transcripts were upre-
gulated in SCZ hGPCs compared to CTR hGPCs (Figure S2A).
qPCR then validated that the expression of a number of trans-
forming growth factor b (TGF-b) pathway regulators, including
BAMBI, was indeed significantly elevated in SCZ GPCs (Fig-
ure S2B). In contrast, these BMP-signaling-related transcripts
did not differ between SCZ and CTR lines at the NPC stage (Fig-
ure S2C). Moreover, the methylation states of CTR- and SCZ-
derived iPSCswere similar (Figure S2D); the little variability noted
across lines in iPSC methylation state appeared due to sex and
line but not to disease state or subject age (Figure S2E). Thus,
the upregulation of BAMBI and other TGF-b and BMP pathway
regulators that we noted in SCZ hGPCs was not due to any sys-
tematic, disease-dependent difference in methylation pattern
between CTR and SCZ cells at the pluripotent stem cell stage.
BMP4 is a strong stimulus for astrocytic differentiation by
hGPCs, and BAMBI is a strong antagonist to BMP4-induced glial
induction, acting as a pseudo-receptor and hence dominant-
negative inhibitor of BMP signaling (Sim et al., 2006). Yet BAMBI
expression may be activated by TGF-b- and BMP-receptor-
dependent signaling as a compensatory negative feedback
response (Onichtchouk et al., 1999). Accordingly, our RNA-seq,3834 Cell Reports 27, 3832–3843, June 25, 2019qPCR data revealed that both BMP-
signaling-dependent transcripts andBAMBI
were upregulated in SCZ hGPCs but not in
SCZ human NPCs (hNPCs) (Figures S2B
andS2C). These data suggest that the upre-
gulation of BMP signaling was specific toSCZ glia and first appeared at the glial progenitor stage and that
this process was associated with the upregulated expression of
BAMBI, which in turn suppressed the astrocytic differentiation of
SCZ hGPCs.
On that basis, we asked whether BAMBI overexpression in
hGPCs derived from normal CTR subjects might mimic or repro-
duce the SCZ GPC phenotype by suppressing the differentiation
of these hGPCs. To that end, we genetically modulated the
expression of BAMBI in hGPCs, both SCZ and CTR-derived
GPCs (Figure S3). We found that overexpression of BAMBI in
CTR GPCs significantly decreased their efficiency of astrocytic
transition (4 CTR lines with 3 repeats/each line, mean of 4 CTR
lines/36.4% ± 4.3%), yielding cells that resembled SCZ hGPCs
in their refractoriness to terminal astrocytic maturation (4 SCZ
lines with 3 repeats/each line, mean of 4 SCZ lines/45.5% ±
3.6%; p = 0.12 by two-tailed t test) (Figures 2A and 2B). However,
BAMBI KD in SCZ GPCs did not rescue astrocytic differentiation
in the latter, suggesting that BAMBI overexpression contributed
to the resistance of SCZ hGPCs to maturation but was not suffi-
cient in this regard (Figures 2A and 2B). Accordingly, when we
used qPCR to assess the expression of alternative inhibitors of
BMP signaling, we found that the mRNAs encoding both follista-
tin (FST) and gremlin1 (GREM1), two potent antagonists of BMPs
and BMP-dependent signaling, were both significantly upregu-
lated by SCZ GPCs (SCZ versus CTR; 4 SCZ and 4 CTR lines,
3 repeats/each line; delta-delta-Ct [ddCt] of FST = 2.45 ± 0.39,
p < 0.05; GREM1 = 3.38 ± 0.53, p < 0.01; two-tailed t test)
(Figure 2C).
Astrocytic Differentiation by SCZGPCsMayBeRescued
by SMAD4 KD
SMAD4 is necessary for canonical BMP signaling in that it acts
as a common effector for multiple upstream signals, in response
to which it translocates to the nucleus, where it activates both
AB C
Figure 2. BAMBI Expression in Normal hGPCs Phenocopied the
Glial Differentiation Defect of SCZ
(A) Upper panel: lentiviral (LV) overexpression of the membrane-bound BMP
antagonist BAMBI in CTR hGPCs (CTR-LV-BAMBI) 4 CTR lines, 3 repeats/
each line) significantly decreased their efficiency of astrocytic transition (4 CTR
lines, 3 repeats/each line). Lower panel: however, BAMBI knockdown (KD) in
SCZ hGPCswas not sufficient to restore astrocytic differentiation (4 SCZ lines,
3 repeats/each line).
(B) Quantification of the proportion of GFAP-expressing astrocytes confirmed
that BAMBI overexpression suppressed the efficiency of astrocytic differen-
tiation of CTR hGPCs to a level indistinguishable from that of SCZ hGPCs,
while BAMBI KD in SCZ hGPCs was not sufficient to rescue astrocytic
differentiation to control levels.
(C) Besides BAMBI, the BMP antagonists follistatin (FST) and gremlin1
(GREM1) were also upregulated in SCZ hGPCs relative to controls.
Scale: 50 mm; ***p < 0.001, one-way ANOVA for (B); **p < 0.001 by two-tailed
t test for (C); NS: not significant; mean ± SEM.BMP- and TGF-b-regulated genes (Herhaus and Sapkota, 2014).
These include BAMBI as well as FST and GREM1, all acting in
concert as negative feedback regulators of pro-gliogenic BMP
signals (Brazil et al., 2015; Onichtchouk et al., 1999) (Figure 3A).
On that basis, we posited that SMAD4KD in hGPCs, by inhibiting
the early expression of BAMBI, FST, and GREM1, might poten-
tiate astrocytic differentiation from hGPCs. Furthermore, to the
extent that the differentiation block in SCZ hGPCs was due to
the SMAD4-mediated overexpression of endogenous BMP in-
hibitors, we postulated that SMAD4 KDwould therefore differen-
tially potentiate astroglial differentiation by SCZ hGPCs. To
test this possibility, we used doxycycline (DOX) induction of
SMAD4 short hammerhead RNA interference (shRNAi) to condi-
tionally KD SMAD4 expression in both SCZ and CTR hGPCs and
then assessed their expression of BMP-regulated genes by
qPCR (Figures S4A–S4C). We found that SMAD4 KD indeed
repressed the expression of BMP-signaling-dependent genes,
including BAMBI, FST, and GREM1 (SCZ-LV-Scrambled versus
SCZ-LV-SMAD4-shRNA; 4 different patient iPSC lines/group,3 repeats/line; ddCt of BAMBI: 2.56 ± 0.35, p < 0.05; FST: 2.38
± 0.24, p < 0.01; GREM1: 3.04 ± 0.45, p < 0.05; all comparisons
by ANOVA with post hoc t tests) (Figure 3B). Importantly, tran-
sient DOX-induced SMAD4 KD, in which shRNAi expression
was limited to the progenitor stage, robustly promoted the astro-
cytic differentiation of the SCZ GPCs, overcoming their relative
block in glial differentiation to effectively rescue astrocytic
phenotype (Figures 3C and 3D). In particular, SMAD4 KD in
SCZ GPCs restored their efficiency of GFAP-defined astrocytic
differentiation to that of CTR GPCs (SCZ-SMAD4-shRNA at the
GPC stage: 56.8% ± 3.8%; CTR lines: 62.2% ± 4.0%; p >
0.05, one-way ANOVA; mean ± SE of 4 distinct patient lines/
group, n R 3 replicates/line) (Figures 3C and 3D). In contrast,
continuous SMAD4 KD after astrocytic induction, as mediated
via continuous DOX exposure (as outlined in Figure S4B), caused
a diminution of GFAP-defined astrocytes in both SCZ and CTR
groups (Figures 3C and 3D). Thus, maintenance of mature astro-
cytic phenotype appeared to require ongoing SMAD4 signaling
in SCZ and CTR astrocytes alike.
Together, these data indicate that aberrant BMP signaling in
SCZ GPCs, by driving the excessive expression of inhibitors of
BMP signaling, suppresses astrocytic differentiation and that
this differentiation defect can be rescued by SMAD4 KD. None-
theless, once SCZ GPCs have progressed to astrocytic differen-
tiation, SMAD4 expression is then required for maintenance of
the astrocytic phenotype in CTR and SCZ astrocytes alike,
consistent with its previously described function as the effector
of BMP-mediated astrocytic maturation (Kohyama et al., 2010).
These data indicate that pathological BMP-dependent signaling
in SCZGPCsmay delimit their astrocyticmaturation and suggest
that this cellular pathology may arise in part from the SMAD4-
dependent overexpression of endogenous inhibitors of pro-
gliogenic BMP signaling by GPCs.
SCZ Astrocytes Exhibit Reduced Potassium Uptake
Together with the impaired astrocytic differentiation of SCZ
GPCs, our RNA-seq data suggested that those astrocytes that
do successfully differentiate might nonetheless be functionally
impaired. In particular, the RNA-seq revealed the downregulated
transcription in SCZ GPCs of a broad set of potassium channel
(KCN)-encoding genes, including the Na+-K+ ATPase, Na+-K+/
2Cl cotransporter (NKCC), and Kir-family inwardly rectifying
KCNs (Figure 4A) (Windrem et al., 2017), all of which play impor-
tant roles in potassium uptake by astrocytes (Larsen et al., 2014;
Macaulay and Zeuthen, 2012) (Figure 5A). Among these
dysregulated KCN genes, ATP1A2, SLC12A6, and KCNJ9,
which respectively encode the Na+/K+-ATPase pump, NKCC1
Na+/K+/2Cl cotransporter, and the Kir3.3 voltage-gated K+
channel (Bøttger et al., 2016; Gamba and Friedman, 2009; Les-
age et al., 1995), were substantially downregulated in SCZ lines
compared to the 4 CTR lines; these findings suggested a broad-
based impairment of K+ uptake by SCZ glia.
On the basis of these genomic data, we next askedwhether K+
uptake was actually impaired in SCZ astrocytes. To address this
hypothesis, we first used qPCR to confirm whether these K+
channel-associated genes were dysregulated in SCZ glia. They
were indeed significantly downregulated, thus validating the
RNA-seq analysis (Figures 4B and 5B). We next assessedCell Reports 27, 3832–3843, June 25, 2019 3835
A B
C
D
Figure 3. SMAD4 Regulated the Astrocytic
Differentiation of SCZ GPCs
(A) SMAD4 regulates the expression of TGF-b and
BMP pathway signaling through (1) phosphorylation
of both SMAD2/3 and SMAD1/5/8; (2) SMAD
nuclear translocation and activation of target pro-
moters, including the early induction of the endog-
enous BMP inhibitors BAMBI, follistatin (FST), and
gremlin1 (GREM1); and (3) their subsequent feed-
back inhibition of BMP signals.
(B) BAMBI, FST, and GREM1 were all significantly
overexpressed in SCZ CD140a-sorted hGPCs
relative to control-derived hGPCs. SMAD4 KD in
SCZ hGPCs (4 SCZ lines, 3 repeats/line) then
repressed the expression of BAMBI, FST, and
GREM1 to control levels.
(C) SMAD4 KD in SCZ hGPCs restored astrocytic
differentiation to that of CTR hGPCs (4 SCZ lines, 3
repeats/each line). DOX ()/(+) means short-term/
long-term culture with DOX.
(D) SMAD4 KD after astrocytic induction, as medi-
ated via continuous doxycycline exposure, caused
a loss of GFAP-defined astrocytes in both SCZ and
CTR groups. DOX ()/(+) means short-term/long-
term culture with DOX.
Scale: 50 mm; *p < 0.05, **p < 0.01, ***p < 0.001; one-
way ANOVA; NS: not significant; mean ± SEM.functional K+ uptake directly in cultured SCZ- and CTR-derived
astrocytes. To obtain mature SCZ and CTR astrocyte cultures,
CD44-sorted glial progenitors were cultured in base media sup-
plemented with 10% fetal bovine serum (FBS) and 20 ng/ml
BMP4 for 4 weeks, so as to potentiate the differentiation of
mature, glial fibrillary acidic protein (GFAP)-expressing, fiber-
bearing astrocytes (Figure S5). Under these highly astrogliogenic
conditions, and using cells already sorted for the early astrocytic
marker CD44, astrocytic maturation was achieved by both SCZ-
and CTR-derived progenitors (Figure S5). Astrocytes from 4
different SCZ and 4 different CTR lines were then incubated3836 Cell Reports 27, 3832–3843, June 25, 2019with 86Rb, a surrogate monovalent cation
for K+ uptake (Larsen et al., 2014), and
rubidium uptake measured as a function
of both cell number and total protein. We
found the K+ uptake in SCZ glia (4 SCZ
cell lines, 5 repeats/each line) was sharply
decreased relative to CTR glia (4 CTR cell
lines, 5 repeats/each line), normalized by
both cell number and total protein (Fig-
ure 5C; p < 0.001 by two-tailed t test).
Since genes encoding different potas-
sium Na+/K+-ATPase pumps, trans-
porters, and inwardly rectifying channels
were dysregulated in SCZ glia, the drugs
ouabain, bumetanide, and tertiapin were
used to respectively block these three
K+ uptake mechanisms. We first tested
different concentrations of each drug to
determine its optimal dose range for
modulating human astroglial K+ uptake.We found that ouabain and bumetanide, respectively targeting
the Na+/K+-ATPase pump and NKCC1-encoded Na+/K+/2Cl
cotransporter, significantly inhibited K+ uptake in CTR glia,
while tertiapin, which targets Kir channels, did not (Figures 5D
and 5E). In marked contrast, neither ouabain nor bumetanide
affected K+ uptake by SCZ astrocytes (Figures 5D and 5E).
This suggests that the functional decrement in K+ uptake by
SCZ-derived astrocytes may be primarily due to downregu-
lated Na+/K+-ATPase and Na+/K+/2Cl cotransporter function,
rendering these cells refractory to ouabain and bumetanide
treatment.
A B
C
Figure 4. REST Represses KCN-Associated
Gene Expression in SCZ hGPCs
(A) Differentially expressed potassium channel
genes in SCZ-derived hGPC lines. Each SCZ-
derived hGPC line was individually compared
against three pooled CTR-derived hGPC lines (FDR
5%, fold change [FC] > 2.00 [if applicable]). Genes
shown were found differentially expressed in at least
three out of four assessed SCZ-derived hGPC lines.
(B) qPCR confirmed that potassium-channel-asso-
ciated genes including ATP1A2, SLC12A6, and
KCNJ9 were all significantly downregulated in SCZ
hGPCs (4 SCZ lines, 3 repeats/each line) relative to
CTR cells (4 CTR lines, 3 repeats/each line).
(C) Biobase-Transfac revealed that the majority
of downregulated potassium-channel-associated
genes in SCZ hGPCs from our RNA-seq data were
targets of the REST repressor.
**p < 0.01 by two-tailed t test; mean ± SEM.REST Regulates Potassium Uptake by SCZ Astrocytes
Since a large number of potassium-channel-encoding genes are
dysregulated in SCZ glia, it is difficult to modulate glial K+ uptake
through genetic means targeting individual KCNs alone. To
address this issue, we used Biobase-Transfac analysis, which
was developed to identify regulatory regions common to
different genes, as a means of defining their shared upstream
regulators (Hu et al., 2014). By this means, we attempted to
pinpoint shared regulatory elements within 1 kb of the transcrip-
tion start sites (TSSs) of the SCZ-associated glial genes in our
datasets; our intent was to identify upstream transcription fac-
tors able to modulate these genes as a group. Using a 13 nucle-
otide consensus sequence (CCNNGGTGCTGAA), we deter-
mined that the majority of all downregulated KCN genes were
targets of the neuron restrictive silencing factor (NRSF) REST
(Figure 4C), a potent transcriptional repressor that acts in neural
cells to repress non-neural gene expression (Hirabayashi and
Gotoh, 2010). REST levels are relatively high in rodent oligoden-
drocyte progenitor cells and rise with terminal oligodendroglial
maturation (Dewald et al., 2011); similarly, REST levels rise with
astrocytic differentiation from uncommitted NPCs (Kohyama
et al., 2010). Importantly, REST transcription may be positivelyCell Rmodulated by SMAD1/5/8 through BMP
signaling (Kohyama et al., 2010), such
that the pathologically upregulated BMP
signaling we observed in SCZ hGPCs
might be expected to drive similarly high
levels of REST. On that basis, we queried
our RNA-seq data, which confirmed that
RESTwas indeed significantly upregulated
in SCZ GPCs relative to CTR GPCs (Wind-
rem et al., 2017). We then used qPCR to
confirm that the upregulation of REST
expression by SCZ glia was consistent
across all of the patients in our series (Fig-
ure 6A). Interestingly, while REST levels
have been previously linked to terminal
glial differentiation (Kohyama et al., 2010),the SCZ hGPCs we evaluated were decidedly refractory to glial
differentiation, whether as astrocytes or oligodendrocytes, and
this observation was consistent across all patient samples as-
sessed. Thus, the disease context informed the cellular response
to REST activity.
On the basis of these data, we postulated that the upregulation
of REST in SCZ-derived glia, and their attendant epigenetic
modification, might be sufficient to repress potassium-
transporter- and channel-associated gene expression. To test
this hypothesis, we used lentivirus to overexpress REST in
CTR glial cells and assessed K+ uptake by the transduced cells.
In parallel, we knocked down REST expression in SCZ glia
through lentiviral shRNAi transduction and then similarly as-
sessed K+ uptake by these cells. qPCR validation confirmed
that REST was significantly modulated as intended in both
CTR and SCZ glial cells (Figure S6A). By this means, we found
that in both CTR and SCZ glia subjected to REST overexpres-
sion, that the expression of a number of K+ transport genes,
including SLC12A6, KCNJ9, and ATP1A2, was indeed signifi-
cantly repressed (Figure 6B and 6C). In contrast, the expression
of these genes was strongly upregulated in both CTR and SCZ
cells subjected to REST KD (Figures 6B and 6C). In addition,eports 27, 3832–3843, June 25, 2019 3837
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Figure 5. Potassium Uptake Was Decreased by SCZ Astrocytes
(A) The Na+/K+-ATPase pump, NKCC1 Na+/K+/2Cl cotransporter, and
inwardly rectifying K+ channels are all involved in the regulation of potassium
uptake by astrocytes.
(B) qPCR confirmed that several K+-channel-associated genes were down-
regulated in SCZ CD44+ astrocyte-biased GPCs relative to CTR cells.
(C) SCZ and CTR CD44+ GPCs were cultured in FBS with BMP4 to produce
mature GFAP+ astrocytes, which were then assessed for K+ uptake; the
results were normalized to both total protein and cell number. K+ uptake by
SCZ astrocytes was significantly reduced (4 SCZ lines, 5 repeats/each line)
compared to K+ uptake by CTR astrocytes (4 CTR lines, 5 repeats/each
line).
(D and E) Astrocytes were treated with ouabain, bumetanide, and tertiapin
to assess which potassium transporter classes were functionally impaired in
SCZ astrocytes relative to control (4 lines of each, 4 repeats/line). Both
ouabain and bumetanide efficiently decreased K+ uptake by CTR astrocytes
(D, gray bars), whereas neither affected K+ uptake by SCZ astrocytes
(E, purple bars).
*p < 0.05, **p < 0.01, ***p < 0.001 by two-tailed t test for (B) and (C); ***p < 0.001
by one-way ANOVA for (D); NS: not significant; mean ± SEM.
3838 Cell Reports 27, 3832–3843, June 25, 2019we next found that BMP4 treatment of CTR GPCs significantly
upregulated REST expression and downregulated K+ transport
gene expression relative to untreated cells, which was restored
with BMP signaling inhibitor DMH1 (Figure S6B), and that lentivi-
ral-SMAD4-shRNAi transduction of SCZ GPCs robustly
repressed REST expression and enhanced K+ transport gene
expression (Figure S6C).
Importantly, we noted that REST-overexpressing CTR astro-
cytes mimicked the functional potassium dysregulation of SCZ
glia, in that their K+ uptake was significantly reduced compared
to that of untreated CTR glia (Figure 6D). Neither ouabain nor
bumetanide further decreased K+ uptake by these cells, sug-
gesting that their targeted pumps and transporters were down-
regulated to the point of functional irrelevance (Figure 6E).
Conversely, K+ uptake by SCZ astrocytes subjected to REST
KD was strongly increased to levels no different from those of
CTR astrocytes (Figure 6D); both ouabain and bumetanide
were then able to significantly reduce K+ uptake by these
REST shRNAi-transduced SCZ astrocytes (Figure 6F). Together,
these data suggest that REST KD in SCZ glia promoted
the restoration of normal K+ uptake by these cells by rescuing
their expression of both Na+/K+-ATPase and the NKCC1 Na+/
K+/2Cl cotransporter, thereby restoring a salient feature of
astroglial potassium homeostasis (Figure 6G). As such, these
observations indicate that REST operates to suppress K+ uptake
by SCZ glia by broadly suppressing the expression and hence
function of multiple mechanisms of glial potassium transport.DISCUSSION
Our data indicate that astrocytic differentiation is impaired in
GPCs derived from childhood-onset schizophrenics and that
this maturational defect may be rescued by the suppression of
either BMP signaling via SMAD4 KD or by the de-repression of
glial-differentiation-associated transcription via REST KD.
Importantly, astrocytic depletion has been recently noted in
both cortical and subcortical regions of patients with SCZ, and
this might be especially prominent in the white matter (Rajkow-
ska et al., 2002; Steffek et al., 2008; Williams et al., 2013). Astro-
cytes play key contributions to neural circuit formation and
stability (Christopherson et al., 2005; Clarke and Barres, 2013).
Thus, any such developmental defect of astrocytic differentiation
in SCZ GPCs might lead to profound defects in the initial forma-
tion or stability of neural circuits, a defect that is one of the hall-
marks of SCZ (Penzes et al., 2011). In this regard, our RNA-seq
data suggested upregulated TGFBR and BMP signaling in SCZ
GPCs, which was associated with the activation of downstream
BMP-regulated genes that included BAMBI, a competitive inhib-
itor of pro-gliogenic BMP signaling (Onichtchouk et al., 1999).
We have previously noted that high expression of BAMBI in adult
hGPCs significantly inhibits their astrocytic differentiation as
induced by BMP4 (Sim et al., 2006), suggesting that the patho-
logical elevation of BMP-signaling-induced BAMBI expression
in SCZ hGPCs, relative to normal CTR hGPCs, might be suffi-
cient to suppress their differentiation as mature astrocytes. Be-
sides BAMBI, several other inhibitors of TGF-b/BMP signaling,
including FST and GREM1 (Brazil et al., 2015), were also
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Figure 6. REST KD Restored Potassium Uptake by SCZ Astrocytes
(A) qPCR confirmed that REST was upregulated in both CD140a-sorted SCZ
hGPCs relative to their controls and in CD44-sorted SCZ astrocytic progenitor
cells relative to CTR cells.upregulated by SCZ GPCs; these may have permitted SCZ
hGPCs to avoid astrocytic fate even after BAMBI KD.
Of note, the activation of canonical TGF-b signaling is depen-
dent upon either SMAD2/3 activation via the TGF-b pathway or
SMAD1/5/8 via BMP-receptor-dependent signals; each of these
effectors needs to combine with SMAD4 for nuclear transloca-
tion prior to the activation of their downstream genetic targets
(Hata and Chen, 2016; Herhaus and Sapkota, 2014). Accord-
ingly, we found that SMAD4 KD efficiently suppressed BMP-
signaling-induced expression of endogenous BMP inhibitors
and by so doing robustly promoted the astrocytic differentiation
of otherwise differentiation-resistant SCZ GPCs. Importantly,
this differentiative response of hGPCs to SMAD4 inhibition was
only noted at the hGPC stage and only in SCZ hGPCs; CTR-
patient-derived hGPCs showed no such potentiated differentia-
tion in response to SMAD4 suppression. Thus, the modulation of
SMAD4might represent an appropriate strategy toward relieving
the glial differentiation defect in SCZ.
Glial maturation is precisely regulated in human brain develop-
ment (Goldman and Kuypers, 2015; Molofsky et al., 2012). Astro-
cytes have a multitude of roles in the CNS, including energy
support to both neurons and oligodendrocytes, potassium buff-
ering, neurotransmitter recycling, and synapse formation and
maturation; as such, astrocytes play critical roles in neural circuit
formation and maintenance (Blanco-Sua´rez et al., 2017; Clarke
and Barres, 2013; Verkhratsky et al., 2015). Astrocytes also
contribute to the glymphatic system through the regulation of
cerebral spinal fluid flow through the brain interstitium (Xie
et al., 2013). Thus, the delayed differentiation of SCZ astrocytes
may have significant effects on neural network formation, orga-
nization, and mature function alike.
We found that a number of potassium transporters were
downregulated in SCZ glia. Interestingly, prior genome-wide
association studies (GWASs) have identified an association of
potassium pump, transport, and channel genes with SCZ.
For instance, the chromosome 1q21-q22 locus, containing
KCNN3, has a significant linkage to familial SCZ (Brzustowicz
et al., 2000). KCNN3 is widely expressed in the human brain
and selectively regulates neuronal excitability and neurotrans-
mitter release in monoaminergic neurons (O’Donovan and(B and C) The expression of several K+-transport-associated genes, including
SLC12A6, KCNJ9, and ATP1A2, was significantly repressed in both CTR (B)
and SCZ (C) glia in which REST was overexpressed via lentiviral-REST
transduction (black bars). In contrast, their expression was robustly upregu-
lated in CTR (B) and SCZ (C) cultures in which REST was knocked down via
lentiviral-REST shRNAi transduction (purple bars, 4 CTR and SCZ lines, 3
repeats/each line).
(D) K+ uptake by REST-transduced CTR astrocytes fell, mimicking that SCZ
glia, whereas K+ uptake was rescued in SCZ lines subjected to REST KD.
(E and F) In cultures of CTR glia (E), lentiviral overexpression of REST sup-
pressed K+ uptake, which was not affected by treatment with ouabain or bu-
metanide. In contrast, potassium uptake was restored in SCZ glia subjected to
REST KD and this rescue was reversed by both ouabain and bumetanide (F)
(4 CTR and SCZ lines, 3 repeats/each line).
(G) These data indicate that upregulated REST in SCZ glia may decrease K+
uptake in part by suppressing the expression and function of the Na+/K+-
ATPase pump and NKCC1 transporter.
**p < 0.01 by two-tailed t test for (A); *p < 0.05, **p < 0.01, ***p < 0.001 by one-
way ANOVA for (B)–(F); NS: not significant; mean ± SEM.
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Owen, 1999). In addition to KCNN3, a number of other KCN
genes have been associated with SCZ, including KCNQ2 and
KCNAB1 (Lee et al., 2013). More recently, a novel de novomuta-
tion in ATP1A3, a subunit of the sodium-potassium pump, has
been specifically associated with childhood-onset SCZ (Smede-
mark-Margulies et al., 2016).
The downregulation or dysfunction of these potassium trans-
porters in GPCs and their derived astrocytes may contribute
significantly to disease phenotype in SCZ. KCN, pump, and
transport genes are widely expressed in both GPCs (Coppi
et al., 2013; Maldonado et al., 2013) and astrocytes (Larsen
et al., 2014; Zhang and Barres, 2010), in which they regulate
not only proliferation, migration, and differentiation but also the
relationship of glia to neurons (Coppi et al., 2013; Maldonado
et al., 2013). In regards to the latter, astrocytes also regulate syn-
aptic K+ uptake through all three major K+ transport mecha-
nisms, including the Na+/K+-ATPase, the NKCC1 cotransporter,
and inwardly rectifying Kir channels (Larsen et al., 2014; Zhang
and Barres, 2010), thereby establishing neuronal firing thresh-
olds over broad regional domains.
Accordingly, dysregulated K+ transport andKCNgene expres-
sion have been associated with a broad variety of neurological
and psychiatric diseases. Several Kir genes, including Kir4.1,
are involved in astrocytic potassium buffering and glutamate up-
take, and deletion of these genes has been noted in both Hun-
tington’s disease and multiple sclerosis (Seifert et al., 2006;
Tong et al., 2014). In addition, mutation of astrocytic ATP1A2,
the a2-isoform of the sodium-potassium pump, may be causally
associated with familial hemiplegicmigraine (Bøttger et al., 2016;
Swarts et al., 2013). In all of these examples, glial K+ uptake is
impaired, just as in SCZ glia, and all are associatedwith elements
of phenotypic hyperexcitability. Indeed, elevated extracellular K+
has been shown to alter the neuronal excitability and neural cir-
cuit stability in a mouse model of SCZ (Crabtree et al., 2017).
Thus, the decreased K+ uptake of SCZ glia may be a significant
contributor to SCZ pathogenesis, especially in regards to those
schizophrenic phenotypes associated with hyperexcitability and
seizure disorders, which would be potentiated in the setting of
disrupted potassium homeostasis.
We next established that the upregulated REST in SCZ glia ap-
pears both necessary and sufficient for their suppression of both
KCN gene expression and potassium uptake. REST, as a tran-
scriptional repressor, regulates neural gene expression in both
neurons and glia (Bruce et al., 2004; Dewald et al., 2011). In
broad terms, REST represses neural genes through its recruit-
ment of CoREST and mSIN3a, the complex of which further
recruits HDAC1/2 and methyltransferase G9a to promote con-
current histone deacetylation and methylation, which together
serve to block transcription (Hirabayashi and Gotoh, 2010). As
such, the misdirected upregulation of REST inhibits KCN gene
expression and thereby contributes to the disease phenotype
of those disorders associated with dysregulated potassium
homeostasis and its attendant neuronal hyperexcitability. For
instance, upregulated REST in peripheral sensory neurons in-
duces the downregulation of KCNQ2, which in turn potentiates
the hyperexcitability of sensory neurons and hence the mainte-
nance of neuropathic pain (Rose et al., 2011). REST similarly re-
presses KCNQ3 gene expression, and the downregulation of3840 Cell Reports 27, 3832–3843, June 25, 2019KCNQ3 by REST provokes neuronal hyperexcitability in specific
neonatal epilepsies (Mucha et al., 2010).
Furthermore, REST is involved in SCZ through its modulation
of miR137 (Warburton et al., 2015), which regulates multiple
SCZ-associated genes, including CACNA1C, TCF4, and
ANK3 (Kwon et al., 2013; Schizophrenia Psychiatric Genome-
Wide Association Study (GWAS) Consortium, 2011). REST
has been reported to be highly expressed in postmortem brain
tissues from patients with SCZ (Loe-Mie et al., 2010). Other in-
vestigators have reported that REST can repress the expres-
sion of potassium-channel-associated genes (Bruce et al.,
2004) and can suppress oligodendroglial differentiation within
the glial lineage (Dewald et al., 2011). We thus hypothesized
that pathologically high levels of REST might repress K+-trans-
porter- and channel-associated gene expression, and thereby
decrease K+ uptake, in SCZ-derived glia. This would be ex-
pected to lead to high interstitial K+ and hence to relative
neuronal hyperexcitability and network desynchronization.
That said, the role of REST in disordered glial potassium ho-
meostasis has not hitherto been reported. Our data suggest
the likelihood that some fraction of schizophrenic patients
might suffer high interstitial K+ levels as a function of diminished
glial potassium uptake. This would be expected to yield
neuronal hyperexcitability as has been reported in Huntington’s
disease, another disorder characterized by glial KCN dysfunc-
tion (Benraiss et al., 2016). As such, our observation of a REST-
dependent impairment of K+ uptake by SCZ-derived glia sug-
gests that REST might be an effective target for the treatment
of SCZ. In that regard, several REST-targeted drugs have
been developed for epilepsy and Huntington’s disease,
including valproic acid and X5050 (Charbord et al., 2013; Gra¨ff
and Tsai, 2013); our data suggest that these agents may have
therapeutic utility in SCZ as well.
Thus, our data reveal the defective differentiation into astro-
cytes by SCZ GPCs, the potential reversibility of that defect by
SMAD4 KD, and the differentiation-coupled, REST-dependent
suppression of KCN gene expression and concomitant defective
uptake of K+ by SCZ glia. The resultant deficiencies in synaptic
potassium homeostasis may be expected to significantly lower
neuronal firing thresholds while accentuating network desynch-
ronization (Benraiss et al., 2016). As such, one might expect that
positive modulators of glial K+ uptake may have real value in the
treatment of SCZ (Calcaterra et al., 2016; He et al., 2013; Rah-
manzadeh et al., 2017). Together, these findings identify a causal
contribution of astrocytic pathology to the neuronal dysfunction
of SCZ and in so doing suggest a set of tractable molecular tar-
gets for its treatment.STAR+METHODS
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Goldman. He may be contacted at: steven_goldman@urmc.rochester.edu or goldman@sund.ku.dk.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patient identification, protection and sampling
Patients from which these lines were derived were diagnosed with disabling degrees of schizophrenia with onset in early adoles-
cence; all patients and their guardians were consented/assented by a child and adolescent psychiatrist working under the supervi-
sion of one of us (RLF), and under the auspices of an approved protocol of the University Hospitals Case Medical Center Institutional
Review Board, blinded as to subsequent line designations. No study investigators had access to patient identifiers.
Cell sources and lines
Schizophrenia-derived iPSC lines were produced from subjects with childood-onset schizophrenia, and control lines were produced
from age- and gender-appropriate control subjects; all iPSC lines were derived as previously reported (Windrem et al., 2017). An
additonal control line (C27; Wang et al., 2013) was graciously provided by Dr. Lorenz Studer (Memorial Sloan Kettering). Control-
derived lines included: CWRU-22 (26 year-old male),37 (32 year-old female),208 (25 year-old male), and C27; SCZ-derived lines
included CWRU-8 (10 year-old female),51(16 year-old male),52 (16 year-old male),193 (15 year-old female),164 (14 year-old
female),29 (12 year-old male),30 (12 year-old male), and31 (12 year-old male) (Windrem et al., 2017; see Table S1). CWRU-51/
52 and CWRU-29/30/31 comprised different lines from the same patients, and were assessed to estimate inter-line variability from
single patients. All iPSCs were generated from fibroblasts by retroviral expression of Cre-excisable Yamanaka factors (Oct4, Sox2,
Klf4, c-Myc) (Takahashi et al., 2007), with validation of pluripotency and karyotypic stability as described (Windrem et al., 2017).
METHOD DETAILS
hiPSC culture and passage
hiPSCs were cultured on irradiated mouse embryonic fibroblasts (MEFs), in 0.1% gelatin (Sigma G1890-100G)-coated 6-well plates
with 1-1.2 million cells/well in hESC medium (see below) supplemented with 10 ng/ml bFGF (Invitrogen, 13256-029). Media changes
were performed daily, and cells passaged at 80% confluence, after 4-7 days of culture. For hiPSC passage, cells were first incubated
with 1ml collagenase (Invitrogen, 17104-019) at 37C for 3-5 minutes, and then cells were transferred into a 15mL tube for centrifuge
with 3 minutes. The pellet was re-suspended with ES medium with bFGF, and was plated onto new irradiated MEFs at 1:3-1:4.
GPC and astrocytic generation from hiPSCs
When hiPSCs reached 80% confluence, they were incubated with 1 mL Dispase (Invitrogen, 17105-041) to permit the generation of
embryoid bodies (Ebs); these were cultured in ES medium without bFGF for 5 days. At DIV6, Ebs were plated onto poly-ornithine
(Sigma, P4957) and laminin (VWR, 47743)-coated dishes, and cultured in neural induction media (NIM; see below) (Wang et al.,
2013), supplemented with 20 ng/ml bFGF, 2 mg/ml heparin and 10 mg/ml laminin for 10 days.
At DIV 25, the Ebs were gently scraped with a 2 mL glass pipette, then cultured in NIM plus 1 mM purmorphamine (Calbiochem,
80603-730) and 0.1 mMRA (Sigma, R2625). At DIV 33, NPCs appeared and were serially switched to NIM with 1 mM purmorphamine
and 10 ng/ml bFGF for 7 days, followed by glial induction medium (GIM) (Wang et al., 2013), with 1 mM purmorphamine for another
15 days. At DIV 56, the resultant glial spheres were mechanically cut with microsurgical blades under a dissection microscope, and
switched to GIM with 10 ng/ml PDGF, 10 ng/ml IGF, and 10 ng/ml NT3, with media changes every 2 days. At DIV 80-100, CTR GPCs
were cultured with 10 ng/ml BMP4 (PeproTech, AF-120-05ET) and 0.5 mMDMH1 (Sigma, D8946-5MG) for 2 weeks, and SCZ GPCs
were transduced with lentiviral-SMAD4-shRNAi for 2 weeks, both of which were used for validation of REST and K+ transport gene
expression. At DIV 150-180, GPCs were incubated with mouse anti-CD44 microbeads (1:50), and then incubated with rabbit anti-
mouse IgG2a+b micro-beads (1:100) and further sorted by magnetic cell sorting (MACS) with a magnetic stand column. The
CD44+ cells were then matured as astrocytes in M41 supplemented with 10% FBS (VWR, 16777-014) plus 20 ng/mL BMP4 for
4 weeks.
Media recipes are listed in Table S2 (hESC and neural media) and S3 (Glial and Astrocyte induction media).
FACS/MACS sorting
Cells were incubatedwith Accutase (Fisher Scientific, SCR005) for 5minutes at 37C to obtain a single cell suspension, and then spun
down at 200RCF for 10 minutes. These GPCs were re-suspended in cold Miltenyi Wash buffer with primary antibody (phycoerythrin
(PE)-conjugated mouse anti-CD140a, 1:50, for FACS; mouse anti-CD140a, 1:100, for MACS), and incubated on ice for 30min, gently
swirling every 10 minutes. After primary antibody incubation, these cells were then washed and either incubated with a secondary
antibody (rabbit anti-mouse IgG2a+b micro-beads, 1:100) followed by sorting on a magnetic stand column for MACS, or directlyCell Reports 27, 3832–3843.e1–e6, June 25, 2019 e4
sorted by FACS on a FACSAria IIIu (Becton Dickinson). The sorted cells were counted and plated onto poly-ornithine- and laminin-
coated 24-well plate for further experiments. Antibodies and dilutions used see Key Resources Table.
RT-PCR
Total RNAwas extracted from cell lines with miRNeasymini kit (QIAGEN, 217004), and thenwas reversely transcribed into cDNAwith
Taqman Reverse Transcription kit (Fisher Scientific, N8080234). The relative expression of mRNA was measured by the Bio-RAD
S6048, which was further normalized to the expression of 18S mRNA.
The primer sequences are listed in Table S4.
Methylation
DNA was extracted from iPSC lines with the QIAamp DNA micro kit (QIAGEN, 56304), and then whole genome methylation analysis
was performed using Illumina Methylation Epic arrays; this was done at the UCLA Neuroscience Genomics Core. Raw data from
Intensity Data (IDAT) files were imported into R and normalized with the preprocessQuantile function from the package minfi (Aryee
et al., 2014). Probes with poor quality signal were eliminated based on set threshold of detection p values (> 0.01). Probes were also
eliminated if they map to the sex chromosomes, to multiple genomic locations, or if they contain single nucleotide polymorphisms at
the CpG site. Following preprocessing, samples were assessed by principal component analysis (native R functions, https://www.
R-project.org) based on their features of methylated intensities (M-values). To determine if a covariate (sex, age, cell line, etc.) could
explain variation in our samples’ methylation landscape, a linear regression model was fit for covariates and each principal compo-
nent. Covariates with significant p values (< 0.05) were highlighted, indicating meaningful relationship between changes in the
covariate (predictor variable) and changes in the principal component values (response variable).
In vitro immunocytochemistry
Cells were first fixed with 4% paraformaldehyde for 5 minutes at room temperature. After washing with D-PBS (Invitrogen, 14190-
250) with thimerosal (Sigma, T5125) for 3 times, cells were penetrated with 0.1% saponin (Fluka Analytical, 47036) plus 1% of either
goat or donkey serum for 15 minutes at room temperature. Cells were further blocked with 5% of either goat or donkey serum plus
0.05% saponin for 15 minutes at RT. After incubation with primary antibodies at 4C overnight, the cells were incubated with sec-
ondary antibodies for 30 min at RT. The counts of immunofluorescent cells were taken from 10 random fields per each replicate,
and each sample had three replicates.
Antibodies and dilutions used see Key Resources Table.
Molecular cloning and viral construction
REST shRNAs of humanREST (target sequences: GCAGTGGCAACATTGGAATGG or CGGCTACAATACTAATCGA) were cloned into
the vector pTANK-EF1a-CoGFP-Puro-WPRE immediately downstream puromycin. The human cDNAs encoding REST (a gift of Ste-
phen Elledge, Addgene 41903) (Westbrook et al., 2008) and SMAD4 (GEHealthcare,MHS6278) were cloned downstreamof the EF1a
promoter in pTANK-EF1a-IRES-mCherry-WPRE (Benraiss et al., 2016). The lentiviral vector allowed for expression of REST and
SMAD4 in tandem with the reporter mCherry. SMAD4 Doxycycline-inducible shRNAs of human SMAD4 (Gene target sequence:
TGGTCAGCCAGCTACTTAC or ATGAATATGACTCACTTCT) in pSMART-TRE3G-EGFP-Puro-WPRE were ordered from GE Health-
care (V3SH11252). BAMBI The human shRNA and cDNA of BAMBI were generated previously (Sim et al., 2006). The final constructs
were validated for the correct insertion by sequencing. The plasmids were then co-transfected with pLP-VSV (Invitrogen, K497500)
and psPAX2 (a gift from Didier Trono, Addgene 12260) into 293FT cells (Fisher Scientific, R70007) through X-tremeGENE (Roche,
06366236001) for lentiviral generation. The supernatants of 293T cells were then collected and spun at 76000 RCF for 3 hr to concen-
trate virus (Beckman L8-70, Ultracentrifuge). A 10-fold serial dilution of virus was then prepared and transduced into 293T cells, and
fluorescent colonies counted to estimate viral titer.
Cell transduction
CD140a+ hGPCswere isolated byMACS and then transducedwith either lenti-TRE3G-SMAD4-shRNAi or lenti-EF1a-BAMBI-shRNAi,
or their respective scrambled control viruses,MACS-sorted CD44+ cells were transducedwith either lenti-EF1a-REST-shRNAi or con-
trol virus, each at 1MOI (multiplicities of infection) for 4 hours. Both lenti-EF1a-REST-shRNAi and lenti-EF1a-BAMBI-shRNAi efficiently
inhibited the expression of their target genes ( Figures S3 and S6A). Cells infectedwith lenti-TRE3G-SMAD4-shRNAi were treated with
0.5 mg/ml doxycycline (Fisher, CN19895510) beginning 4 days after viral infection; this was maintained for 1 week prior to experiment
initiation; during this period, the cells were maintained in glial induction media. Under doxycycline, SMAD4 mRNA expression fell
to < 30% of control; no inhibition was noted in the absence of doxycycline (Figures S4A–S4C).
Potassium uptake
Astrocytes were plated onto poly-ornithine- and laminin-coated 24-well plates with 30,000 cells/well. For the potassium uptake
assay, astrocytes were incubated with 86Rb (1.0-3.3uCi/well) for 15min, and then they were washed three time with ice-cold artificial
cerebrospinal fluid (aCSF, 500uL/well). 0.5N NaOH (200uL/well) was put into each well for cell lysis, which was put into 5ml cocktail
liquid (Ultima Gold, Fisher Scientific, 509050575) and measured by scintillation counter (Beckman Coulter, LS6500), and the resultse5 Cell Reports 27, 3832–3843.e1–e6, June 25, 2019
were normalized to both total protein (BCA Protein Assay Kit, Fisher Scientific, 23227) and cell number (Hemocytometer, Fisher
Scientific, 02-671-54). The aCSF solution contained (in mM): 124 NaCl, 2.5 KCl, 1.75 NaH2PO4, 2 MgCl2, 2 CaCl2, 0.04 vitamin C,
10 glucose and 26 NaHCO3, pH 7.4.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical parameters including the exact n, the center, dispersion, precisionmeasures (mean ±SEM), and statistical significance are
reported in the Figures and Figure Legends. All analyses were done with GraphPad PRISM 6 using one-way ANOVA and two tailed
t test. Statistical significance was considered as P values less than 0.05. Significances were represented as *p < 0.05, **p < 0.01 and
***p < 0.001. Graphs and figures were made and assembled with Prism 6.
DATA AND SOFTWARE AVAILABILITY
All raw data have been uploaded to Mendeley data (https://data.mendeley.com), at https://data.mendeley.com/datasets/
wvnxgw7xzf/draft?a=7661a24e-3cb1-4a1b-a072-ba6ac169d909.
Previous data processing and analysis routines from Windrem et al. (2017) are available from https://github.com/cbtncph/
GoldmanetalSCZ2016, while the genomic data from that study have been deposited to GEO: GSE86906.Cell Reports 27, 3832–3843.e1–e6, June 25, 2019 e6
